溶酶体逃逸与核靶向纳米药物增强肿瘤催化内放疗
研究合成125I标记的TiO2-TAT/HA2纳米颗粒,利用TAT/HA2介导溶酶体逃逸与核蓄积,在PANC-1细胞及胰腺癌小鼠模型中评估其增强催化内放疗的效果。结果显示125I-TiO2-TAT/HA2较125I-TiO2显著增加凋亡与DNA损伤、降低DNA修复蛋白表达,并显著缩小肿瘤体积。
要点
- 125I-TiO2-TAT/HA2的标记率平均为90.1%,125I-TiO2为89.0%。
- 体外125I-TiO2-TAT/HA2较125I-TiO2显著增加凋亡和DNA损伤,降低RAD51和53BP1表达(均p<0.05)。
- 体内125I-TiO2-TAT/HA2组肿瘤体积显著小于125I-TiO2组,坏死和凋亡增强(均p<0.05)。
核心结论
- 125I-TiO2-TAT/HA2表现出明显增强的疗效,可能通过活性氧的精确核递送而非增加活性氧产生实现。
- 该策略为改进肿瘤治疗提供了有前景的方法,并可能适用于其他大分子治疗药物。
研究设计与样本
- 研究合成TiO2纳米颗粒与TiO2-TAT/HA2并标记125I,在PANC-1细胞和皮下胰腺癌小鼠模型中评估。
- 体外采用共聚焦显微镜和生物透射电镜观察亚细胞定位,CCK-8法测细胞活力,流式细胞术测凋亡和活性氧,PCNA染色测增殖,γ-H2AX免疫荧光测DNA损伤,蛋白质印迹测DNA修复蛋白表达。
- 体内通过荧光成像追踪Cy5标记纳米颗粒的瘤内滞留,SPECT监测125I-TiO2-TAT/HA2,小鼠接受瘤内注射DMEM、125I、125I-TiO2或125I-TiO2-TAT/HA2,记录肿瘤体积、体重和生存。
- 治疗前后用18F-FDG PET/CT评估肿瘤糖代谢,并行H&E、TUNEL及Ki-67和DNA修复蛋白免疫组化染色。
主要发现
- 125I-TiO2和125I-TiO2-TAT/HA2的标记率平均分别为89.0%和90.1%。
- 共聚焦显微镜和生物透射电镜证实TiO2-TAT/HA2具有核靶向能力。
- 体外125I-TiO2-TAT/HA2较125I-TiO2显著增加凋亡和DNA损伤并降低DNA修复蛋白RAD51和53BP1表达(均p<0.05)。
- 125I-TiO2-TAT/HA2还降低PCNA表达并增加活性氧产生(均p>0.05)。
- 体内Cy5-NPs、125I-TiO2和125I-TiO2-TAT/HA2均表现出延长的瘤内滞留。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radio-nanomedicine, such as 125I-labelled TiO2 nanoparticles (125I-TiO2 NPs), presents a promising tumour treatment approach. By leveraging 125I as an electron donor to activate TiO2 NPs and promote γ-ray-induced H2O radiolysis, 125I-TiO2 generates reactive oxygen species (ROS) and induces DNA damage, thus enabling catalytic internal radiotherapy (CIR). Since DNA is a key target of radiation and ROS-induced damage, enhancing nuclear delivery is critical. However, lysosomal entrapment of 125I-TiO2 NPs greatly restricts the efficacy of CIR. To overcome this limitation, we conjugated 125I-TiO2 with transactivator of transcription/hemagglutinin-2 (125I-TiO2-TAT/HA2), hypothesising that TAT/HA2-mediated lysosomal escape and nuclear accumulation could improve the anti-tumour effects of 125I-TiO2. METHODS: TiO2 NPs and TiO2-TAT/HA2 were synthesised and labelled with 125I. Subcellular localisation was observed by confocal microscopy and biological transmission electron microscopy (bio-TEM). The effects of 125I-TiO2-TAT/HA2 on PANC-1 cells were assessed by the CCK-8 assay (cell viability), flow cytometry (apoptosis and ROS generation), proliferating cell nuclear antigen (PCNA) staining (proliferation), γ-H2AX immunofluorescence (DNA damage), and western blotting (DNA repair protein expression). In a subcutaneous pancreatic cancer mouse model, the intratumoural intra-tumoural retention of cyanine 5-labelled NPs (Cy5-NPs) was tracked via fluorescence imaging, whereas 125I-TiO2-TAT/HA2 was monitored by single-photon emission computed tomography (SPECT). Mice received intra-tumoural injections of DMEM, 125I, 125I-TiO2, or 125I-TiO2-TAT/HA2, and tumour volume and mouse weight and survival were recorded. Tumour glycometabolism was evaluated using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) before and after treatment. Haematoxylin and eosin (H&E), TdT-mediated dUTP nick end labelling (TUNEL), and immunohistochemical staining (Ki-67, DNA repair proteins) were performed. RESULTS: The labelling rates of 125I-TiO2 and 125I-TiO2-TAT/HA2 averaged 89.0% and 90.1%, respectively. Confocal microscopy and bio-TEM confirmed the nucleus-targeting ability of TiO2-TAT/HA2. In vitro, 125I-TiO2-TAT/HA2 significantly increased apoptosis and DNA damage and reduced DNA repair protein expression (RAD51and 53BP1) versus 125I-TiO2 (all p < 0.05). 125I-TiO2-TAT/HA2 additionally reduced PCNA expression and increased ROS production (both p > 0.05). In vivo, Cy5-NPs, 125I-TiO2, and 125I-TiO2-TAT/HA2 exhibited prolonged intra-tumoural retention. Tumours treated with 125I-TiO2-TAT/HA2 displayed a significantly smaller volume, enhanced necrosis and apoptosis (H&E, TUNEL), and downregulated DNA repair protein expression (all p < 0.05) and reduced Ki-67 expression (p > 0.05) compared with the effects of 125I-TiO2. CONCLUSION: 125I-TiO2-TAT/HA2 exhibited markedly enhanced efficacy, likely through the precise nuclear delivery of ROS rather than increased ROS production. This strategy presents a promising method to improve tumour therapy, and it could be adapted for other macromolecular therapeutics.
引用
- Su W, Wang H, Zhao S, et al. Lysosome-escaping and nucleus-targeting nanomedicine for enhanced cancer catalytic internal radiotherapy. Eur J Nucl Med Mol Imaging. 2025. PMID: 40590905. doi:10.1007/s00259-025-07432-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。